25 completed, 7 unknown, 3 recruiting, 3 terminated. 40 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 40 | Completed 25, Unknown 7, Recruiting 3, Terminated 3, Withdrawn 2 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) KVD900 600 mg - Hereditary Angioedema | Phase 4 | Recruiting | KalVista Pharmaceuticals, Ltd. | 100 | 2026-08-17 | 2026-09-17 |
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Garadacimab - Hereditary Angioedema | Phase 4 | Completed | CSL Behring | 18 | 2025-04-28 | 2026-07-23 |
| A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | Nang Kuang Pharmaceutical Co., Ltd. | 5 | 2024-09-27 | 2025-12-18 |
| Lanadelumab in Long-term Prophylaxis of Acquired Angioedema Lanadelumab 300 mg - Angioedema | Phase 4 | Recruiting | Bernstein Clinical Research Center | 5 | 2024-06-01 | 2025-02-25 |
| Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU) human histaglobulin, placebo, Loratadine 10 Mg - Chronic Spontaneous Urticaria | Phase 4 | Unknown | Hangzhou Grand Biologic Pharmaceutical, Inc. | 252 | 2024-03-31 | 2024-02-09 |
| Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria omalizumab 300 mg every four weeks, omalizumab 300 mg every six weeks - Chronic Spontaneous Urticaria, Chronic Urticaria, Idiopathic | Phase 4 | Recruiting | Simon Francis Thomsen | 40 | 2024-01-12 | 2025-09-19 |
| Molecular Endotypes of Chronic Idiopathic Urticaria Omalizumab - Chronic Urticaria, Idiopathic | Phase 4 | Unknown | University of Colorado, Denver | 15 | 2022-01-01 | 2024-08-15 |
| Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children probiotics, conventional medical treatment - Rhinitis, Allergic, Asthma | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 200 | 2020-03-01 | 2021-06-24 |
| Tranexamic Acid and Spontaneous Chronic Urticaria association of levocetirizine and tranexamic acid, Levocetirizine only - Chronic Spontaneous Urticaria | Phase 4 | Unknown | University Hospital, Grenoble | 80 | 2019-12-10 | 2021-04-28 |
| A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria Vit D - Urticaria, Vitamin D Deficiency | Phase 4 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 262 | 2019-06-21 | 2019-06-24 |
| Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) Ruconest - Hereditary Angioedema | Phase 4 | Completed | Bernstein Clinical Research Center | 5 | 2018-08-14 | 2024-11-15 |
| A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions C1-esterase inhibitor [recombinant] (C1-INH-R) - CVI - Common Variable Immunodeficiency | Phase 4 | Completed | IMMUNOe Research Centers | 20 | 2018-06-13 | 2021-02-15 |
| Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Omalizumab - Urticaria Chronic | Phase 4 | Completed | Johns Hopkins University | 18 | 2017-10-06 | 2021-06-14 |
| Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody benralizumab, placebo - Chronic Idiopathic Urticaria | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2017-09-12 | 2019-07-10 |
| Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Omalizumab, Placebos - Idiopathic Angioedema | Phase 4 | Completed | University of Wisconsin, Madison | 12 | 2017-03-30 | 2022-11-01 |
| C1-inhibitor in Allergic ASThma Patients C1-inhibitor, Saline, Antibiotics - Asthma | Phase 4 | Terminated | T. van der Poll | 37 | 2016-11-16 | 2020-06-24 |
| Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab - Urticaria | Phase 4 | Withdrawn | Selina Gierer, D.O. | 2016-02-01 | 2018-05-01 | |
| Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Bilastine, Placebo - Allergic Rhinitis, Urticaria | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 19 | 2015-10-01 | 2017-04-18 |
| Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Dapsone, HLA-B*1301 - Allergic Cutaneous Vasculitis, Urticaria | Phase 4 | Unknown | Shandong Provincial Institute of Dermatology and Venereology | 3130 | 2015-07-01 | 2017-03-03 |
| A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Omalizumab, Placebo - Urticaria | Phase 4 | Completed | Genentech, Inc. | 206 | 2015-05-18 | 2018-03-29 |
Showing 20 of 40. Sign in to see all of them.
Chronic Urticaria (14) · Angioedemas, Hereditary (10) · Angioedema (4) · Rhinitis, Allergic (3) · Asthma (2) · Acne Vulgaris (1) · Cold Urticaria (1) · Common Variable Immunodeficiency (1) · Dermatitis, Atopic (1) · Drug-Related Side Effects and Adverse Reactions (1) · Genetic Diseases, Inborn (1) · Hereditary Angioedema Types I and II (1) · Hypersensitivity (1) · Leprosy (1)
Hypersensitivity, Immediate (40) · Immune System Diseases (40) · Skin Diseases (40) · Skin Diseases, Vascular (40) · Skin and Connective Tissue Diseases (40) · Hypersensitivity (39) · Cardiovascular Diseases (15) · Disease Attributes (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Vascular Diseases (15) · Chronic Disease (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Angioedema (10)
desloratadine (9) · Omalizumab (8) · levocetirizine (5) · Complement C1 Inhibitor Protein (4) · Cetirizine (3) · icatibant (3) · SERPING1 protein, human (2) · bilastine (2) · fexofenadine (2) · Anti-Bacterial Agents (1) · Ciprofloxacin (1) · Complement C1 (1) · Dapsone (1) · Hydroxyzine (1) · Injections (1)
Organon and Co (5) · Bernstein Clinical Research Center (2) · CSL Behring (2) · Charite University, Berlin, Germany (2) · University of Colorado, Denver (2) · Assistance Publique - Hôpitaux de Paris (1) · Association Asthma, Bulgaria (1) · Genentech, Inc. (1) · Grupo de Alergología Clínica y Experimental (1) · Hangzhou Grand Biologic Pharmaceutical, Inc. (1) · IMMUNOe Research Centers (1) · Johns Hopkins University (1) · Jonathan A. Bernstein, MD (1) · KalVista Pharmaceuticals, Ltd. (1) · Lotus Pharmaceutical (1)
United States (15) · Germany (5) · France (4) · Bulgaria (2) · China (2) · Italy (2) · Romania (2) · Taiwan (2) · Belgium (1) · Canada (1) · Colombia (1) · Denmark (1) · Hungary (1) · India (1) · Malaysia (1)
Jonathan Bernstein, MD (2) · Marcus Maurer, MD (2) · Aleena Banerji, M.D. (1) · Davinder Parsad, MD (1)
PMID 19133920, PMID 23147964, PMID 27140403, PMID 27326985, PMID 27788880, PMID 28709817, PMID 29503044, PMID 29671921, PMID 31034999, PMID 31109849, PMID 33713769, PMID 33737935, PMID 34303860, PMID 35914662, PMID 39762098
2008 (1), 2015 (1), R01AI116658 (1)